[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alpha1-antitrypsin-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alpha1-antitrypsin-deficiency":116},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100618051","phase-4-phase-4-double-blind-study-evaluating-the-response-on-computed-tomography-ct-lung-density-decline-rates-of-respreeza--zemaira-weekly-for-3-years-in-adults-with-alpha1-antitrypsin-deficiency-aatd-100618051",false,"NCT07326592","Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza \u002F Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)","A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® \u002F Zemaira® Weekly Intravenous Infusions Administered Over 3 Years as Longterm Maintenance Therapy in Adult Subjects With Emphysema Related to Alpha1 Antitrypsin Deficiency","Inclusion Criteria:\n\n* • Age greater than or equal to (\\>=) 18 and less than or equal to (\\\u003C=) 65 years at the time of providing written informed consent.\n* • Confirmed diagnosis of emphysema related to AATD with either the PiZZ, PiZ(null), or Pi(null\u002Fnull) genotype with documented serum AAT levels less than (\\\u003C) 11 micrometer (μM) (or \\\u003C 50 mg\u002FdL \\[milligram\u002Fdeciliter\\]) at any time before the first administration of CE1226 on Day 1 (Baseline).\n\nExclusion Criteria:\n\n* • Participants should not have acute illness or pulmonary exacerbation within 6 weeks before the first administration of CE1226 on Day 1 (Baseline).\n* • Participants should not have previously received gene therapy for AATD at any point.\n* • Participants with liver disease secondary to AATD.","ALL","18 Years","65 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density decline in alpha-1 antitrypsin (AAT) deficient participants over 3 years as compared with the marketed dose 60 milligrams per kilogram (mg\u002Fkg).",[27,28,29],"Alpha1 Antitrypsin Deficiency","Alpha1-Proteinase Inhibitor Deficiency","Emphysema",[31,32],"Progressive Emphysema","Chronic Pulmonary Disease","NOT_YET_RECRUITING","2026-05-14",{"date":36,"type":37},"2026-05-15","ACTUAL",{"date":39,"type":21},"2026-07-20",{"date":41,"type":21},"2033-09-15",{"name":43,"class":44},"CSL Behring","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100491349","phase-3-study-to-check-the-safety-of-fazirsiran-and-learn-if-fazirsiran-can-help-people-with-liver-disease-and-scarring-fibrosis-due-to-an-abnormal-version-of-alpha-1-antitrypsin-protein-100491349","NCT05677971","Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein","A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis","Inclusion criteria:\n\n* The participant must have a diagnosis of the Z allele homozygotes (PiZZ) genotype AATD. PiZZ diagnosis from source verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.\n* The participant, of any sex, is aged 18 to 75 years, inclusive.\n* The participant's liver biopsy core sample collected should meet the requirements of the protocol.\n* The participant has evidence of METAVIR stage F2, F3, or F4 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading of a previous biopsy conducted within 6 months before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.\n* The participant has a pulmonary status meeting the protocol's requirements.\n* It must be confirmed that the participant does not have HCC. Participants will be screened for HCC with alpha-fetoprotein (AFP) and abdominal ultrasound. If the participant has any of the following, they will be required to have contrast-enhanced CT or MRI imaging to exclude HCC before randomization.\n* An adult participant must have a body mass index (BMI) greater than or equal to (\\>=) 18.0 kilograms per meter square (kg\\^m2).\n* The participant is a nonsmoker for at least 6 months before screening.\n\nExclusion Criteria\n\n* The participant has a history of liver decompensating events (overt hepatic encephalopathy \\[West Haven Grade \\>=2\\] documented by a physician or healthcare professional, clinically significant ascites, spontaneous bacterial peritonitis, GI bleeding from varices, hepatopulmonary syndrome, hepatorenal syndrome, portal pulmonary hypertension, or bleeding portal hypertensive gastropathy).\n* The participant has a history of the presence of medium or large varices or varices with red wale signs based on a previous esophagogastroduodenoscopy (EGD) within 6 months before the estimated enrollment date. For certain participants, an EGD will be required at screening if there is no EGD available within 6 months before the estimated enrollment date. Presence of small varices with no red wale signs on EGD and no history of bleeding will be acceptable for study eligibility.\n* The participant has evidence of chronic liver disease attributable to other diseases, including viral hepatitis B or C, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or autoimmune hepatitis.\n* The participant has alanine transaminase (ALT) or aspartate transaminase (AST) levels \\>250 units per liter (U\u002FL).\n* The participant has a platelet count \\\u003C60,000 per cubic millimeter (mm\\^3) (\\\u003C60 × 10\\^9 per liter \\[10\\^9\u002FL\\]).\n* The participant has albumin \\\u003C=2.8 gram per deciliter (g\u002FdL) (28 grams per liter \\[g\u002FL\\]).\n* The participant has international normalized ratio (INR) \\>=1.7.\n* The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.\n* The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.\n* The participant has previously been treated with fazirsiran or any other RNAi for AATD-LD.\n* The participant has portal vein thrombosis.\n* The participant has a prior transjugular portosystemic shunt procedure.\n* The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with other curatively treated malignancies who have no evidence of metastatic disease and a greater than 1-year disease-free interval may be entered after approval by the medical monitor.","75 Years",{"count":54,"type":21},160,[56],"PHASE3","The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works compared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in the blood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well as to check for side effects in participants treated with fazirsiran compared with those who received placebo.\n\nParticipants will either receive fazirsiran or placebo. Liver biopsies, a way of collecting a small tissue sample from the liver, will be taken twice during this study.",[59],"Alpha1-Antitrypsin Deficiency","RECRUITING","2026-05-08",{"date":63,"type":37},"2026-05-13",{"date":65,"type":37},"2023-03-06",{"date":67,"type":21},"2031-12-12",{"name":69,"class":44},"Takeda",89,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100528789","phase-3-study-to-learn-about-the-safety-of-fazirsiran-and-if-it-can-help-people-with-alpha-1-antitrypsin-liver-disease-with-mild-liver-scarring-fibrosis-100528789","NCT06165341","Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis","Inclusion Criteria:\n\n* In the opinion of the investigator, the participant is capable of understanding and fully complying with the protocol requirements and adhering to the protocol schedule.\n* The participant is able to read, understand, and complete the study questionnaires electronically per the investigator's judgment.\n* The participant signs and dates a written Informed Consent Form (ICF). Any required privacy authorization should also be signed before the initiation of any study procedures.\n* The participant, of any sex, is aged 18 to 75 years, inclusive.\n* The participant must have a diagnosis of the protease inhibitor Z mutation (PiZZ) genotype AATD. A diagnosis of PiZZ from source-verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.\n* The participant's liver biopsy core samples collected as per protocol requirements.\n* The participant has evidence of METAVIR stage F1 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading from a previous biopsy conducted within 1 year before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.\n* The participant has a pulmonary status that meets the protocol requirements.\n* It must be confirmed that the participant does not have hepatocellular carcinoma (HCC).\n* Any participant who is taking statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or beta-1 selective adrenergic receptor inhibitors must have been receiving a stable dose of these medications for at least 8 weeks before randomization. All attempts are to be made for the participant to continue the same dose of the medication for the duration of study participation.\n* An adult participant must have a body mass index (BMI) between 18 and 39 kilogram per meter square (kg\u002Fm\\^2), inclusive.\n* The participant has a 12-lead electrocardiogram at screening that, in the opinion of the investigator, has no abnormalities that could compromise the participant's safety in this study.\n* The participant is a nonsmoker.\n* If the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone less than or equal to \\[\\\u003C=10\\] milligrams per day \\[mg\u002Fd\\] or its equivalent), the doses of the participant's medications must have remained unchanged for greater than or equal to (\\>=) 4 weeks before screening.\n* The participant must have suitable venous access for blood sampling.\n* A person of childbearing potential (POCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 before dosing.\n* The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study and for 6 months after the last dose of study medication. The participant must not donate sperm for at least 6 months after the last dose of study medication.\n\nExclusion criteria:\n\n* The participant has evidence of \\>= F2 fibrosis based on liver biopsy during the screening period.\n* The participant has a history of liver decompensating events.\n* The participant has a history of varices based on a previous esophagogastroduodenoscopy.\n* The participant has portal vein thrombosis.\n* The participant has undergone a prior trans-jugular portosystemic shunt procedure.\n* The participant has evidence of other forms of chronic liver diseases.\n* The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of metastatic disease and disease-free interval greater than (\\>) 1 year may be enrolled after approval by the medical monitor.\n* The participant has an abnormal finding of clinical relevance at the screening evaluation and before administration of the first dose of study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results.\n* The participant has any laboratory abnormalities at screening and before the first dose of the study drug that meet protocol parameters.\n* The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.\n* The participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months before screening. The participant may be screened earlier based on principal investigator (PI) assessment of clinical recovery and return to baseline pulmonary function in discussion with the medical monitor.\n* The participant has a history of frequent pulmonary exacerbations (\\>=2 moderate or severe exacerbations within 52 weeks before screening).\n* The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be rescreened after the clinical resolution of an exacerbation).\n* The participant is receiving long-term, around-the-clock oxygen supplementation or supplemental oxygen with continuous positive airway pressure (CPAP) or bilevel positive airway pressure for acute respiratory failure. The following conditions are allowable for the participant to enter screening: short-term use of oxygen supplementation (example, for the management of acute chronic obstructive pulmonary disease \\[COPD\\] exacerbation) or CPAP for obstructive sleep apnea.\n* The participant has human immunodeficiency virus (HIV) infection as shown by the presence of anti-HIV antibody (seropositive).\n* The participant is seropositive for hepatitis B virus (HBV surface antigen positive and\u002For HBV core antibody positive without HBV surface antibody at screening) or hepatitis C virus (HCV) (detectable HCV Ribonucleic Acid \\[RNA\\] at screening). Cured HCV (positive antibody test without detectable HCV RNA for at least 6 months after treatment) is acceptable.\n* The participant has unstable, poorly controlled, or severe hypertension. Participants may be rescreened once their blood pressure (BP) is successfully controlled.\n* The participant has a history of torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long QT syndrome or new ST-segment elevation or depression or a new Q wave on ECG. Participants with a history of atrial arrhythmias should be discussed with the medical monitor.\n* The participant has symptomatic heart failure (per New York Heart Association guidelines), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction less than \\[\\\u003C\\] 20 percent \\[%\\]), transient ischemic attack, or cerebrovascular accident within 6 months before screening.\n* The participant has a history of major surgery within 12 weeks of screening (or longer, at the discretion of the investigator).\n* The participant has a history of more than moderate alcohol consumption within 12 months before the screening visit.\n* The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.\n* The participant has previously been treated with fazirsiran or any other RNA interference (RNAi) for alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).\n* The participant has a history of hypersensitivity or allergies with any associated excipients of fazirsiran.\n* The participant has received an investigational agent or device within 30 days, or 5 half-lives, whichever is longer, before the dosing of study medication or is currently participating in an investigational study involving a therapeutic intervention.\n* The participant has donated \\>=500 milliliter (mL) of blood within 1 month of the administration of study treatment.\n* The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk. The participant has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurologic, psychiatric, gastrointestinal (GI), systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.\n* The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 6 months before screening, or is taking chronic anticoagulants.\n* This participant is unable to return for all scheduled study visits.\n* The participant has known or suspected coronavirus disease 2019 (COVID-19) that, in the opinion of the sponsor and investigator, does not resolve during screening. Positive antibody testing for COVID-19 without other evidence of current or recent active infection does not exclude participation. Enrollment of participants who fail inclusion due to COVID-19 infection may be temporarily delayed at the discretion of the sponsor and investigator. If the participant has a positive polymerase chain reaction (PCR) with no other evidence of infection, a retest may be allowed; however, to enroll in the study the participant must have a negative PCR.\n* The participant is a study site employee involved in the conduct of this study, an immediate family member (example, spouse, parent, child, sibling), is in a dependent relationship with study site employee who is involved in the conduct of this study or may consent under duress.\n* The participant takes or is required to take excluded medications.\n* The participant is pregnant or breastfeeding or intending to become pregnant before participating in this study, during the study, or within 6 months after last dose of the study drug; or the participant is intending to donate ova during such time period.",{"count":79,"type":21},50,[56],"The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver. People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study.",[59],"2026-03-03",{"date":85,"type":37},"2026-03-05",{"date":87,"type":37},"2024-03-01",{"date":89,"type":21},"2028-08-26",{"name":69,"class":44},41,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100555466","a-study-in-adults-to-learn-about-inherited-alpha-1-antitrypsin-deficiency-aatd-and-aatd-related-liver-problems-100555466","NCT06512454","A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems","Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency and Associated Liver Disease","ALPHATUDE","Inclusion Criteria:\n\nParticipants who meet all the following criteria will be included in the study.\n\nCohorts 1 and 2:\n\n1. Willing to provide written informed consent or currently enrolled in an ongoing participating AATD patient registry that does not require reconsenting to participate in the study.\n2. \\>=18 years of age at enrollment in this study.\n3. Participants with documented diagnosis of AATD, meeting the following criteria:\n\n   1. Cohort 1 (AATD-Pi\\*ZZ genotype\u002Fphenotype).\n\n      • Pi\\*ZZ genotype as documented from rapid genetic assay, sequencing, or polymerase chain reaction (PCR), or Pi\\*ZZ phenotype as documented from iso-electric focusing (IEF) electrophoresis.\n   2. Cohort 2 (AATD-Pi\\*SZ genotype\u002Fphenotype with liver disease manifestation).\n\n      * Pi\\*SZ genotype as documented from rapid genetic assay, sequencing, or PCR, or Pi\\*SZ phenotype as documented from IEF electrophoresis, and\n      * Moderate-advanced or severe liver disease manifestation as defined by either liver biopsy or surrogate laboratory or imaging measures, as determined through:\n\n        * Lab and imaging measures to define liver disease manifestation\n\nExclusion Criteria:\n\nParticipants who meet any following criteria will be excluded from the study.\n\n1. Documented AATD genotype\u002Fphenotype other than Pi\\*ZZ or Pi\\*SZ.\n2. History of liver transplant.\n3. No results for either biopsies, magnetic resonance elastography (MRE), fibro scan (vibration controlled transient elastography \\[VCTE\\]), or Aspartate aminotransferase to platelet ratio index (APRI) in the 24 months prior to the index\u002Fenrollment date and has none of these tests ordered during the index period.\n4. Participants who had previously been treated or in an active participation in an interventional trial studying liver or lung disease.\n5. Treatment with liver directed AATD investigational therapy as part of a compassionate use request.",{"count":101,"type":21},500,"OBSERVATIONAL","The main aim of this study is to learn about liver problems caused by the lack of alpha-1 antitrypsin (called Alpha-1 Antitrypsin Deficiency or AATD) in adults when not treated (this is called the natural history of a condition) over 5 years. Other aims are to learn what can predict the AATD-liver condition starting and getting better or worse, describe how this condition is currently being diagnosed and watched in normal hospital care, and describe how the AATD also affects and adult's lung function.\n\nData in this study will be collected to include medical history of a participant, including the date AATD was first identified and\u002For the date on which the first AATD-related liver or lung problems were diagnosed. At study start and then every year until study end, participants will be asked to completed questionnaires (called patient-reported outcomes or PRO).",[59],[106],"Drug Therapy","2025-10-23",{"date":109,"type":37},"2025-10-24",{"date":111,"type":37},"2024-09-25",{"date":113,"type":21},"2032-04-06",{"name":69,"class":44},2,"Alpha1-antitrypsin Deficiency"]